Reconciling differences in impact of molecular subtyping on response to cisplatin-based chemotherapy

Nat Commun. 2021 Aug 10;12(1):4833. doi: 10.1038/s41467-021-24837-8.

Authors

Mathieu Roumiguie^{1

2}, Alberto Contreras-Sanz³, Gunjan Kumar³, Peter C Black³

Affiliations

¹ Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. [email protected].
² Department of Urology, CHU-Institut Universitaire du Cancer-Oncopôle, Toulouse, France. [email protected].
³ Vancouver Prostate Center, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

No abstract available

Publication types

Letter
Comment

MeSH terms

Chemotherapy, Adjuvant
Cisplatin*
Neoadjuvant Therapy*

Substances

Cisplatin